Projected Benefits of Gout Control on the Health and Economic Burden of CKD Patients with Uncontrolled Gout

作者
Brad A. Marder,Joshua Card-Gowers,Lise Retat,Marek Piotrowski,Laura Webber,Brian D. LaMoreaux,Ada Kumar
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:34 (11S): 660-661
标识
DOI:10.1681/asn.20233411s1660c
摘要

Background: Gout affects 1 in 4 patients with stage 3-5 CKD and is an independent risk factor for CKD progression. Since oral urate lowering therapies (ULTs) cannot adequately manage gout in some CKD patients, this study examines potential benefits of pegloticase treatment in CKD patients with refractory gout. Methods: A validated microsimulation model was used to project gout burden in a virtual US CKD population. In the baseline scenario, individuals were assigned an eGFR, albuminuria status, and serum urate (SU) level. Those with gout were assigned complication risks for stroke, diabetes, and hypertension, direct and indirect costs, oral ULT use/efficacy probability (use: 29.9-41.9% [based on eGFR], efficacy: 48.3%) and utility weight. In the intervention scenario, patients with uncontrolled gout (SU>6 mg/dL despite oral ULT, and ≥2 gout flares/year or ≥1 tophi) were “treated” with pegloticase, assuming a 71% SU-lowering efficacy rate (SU<6mg/dL) through simulation end. Health/economic benefits were projected through 2035. Results: Prevalence of comorbid gout and CKD was projected to rise from 8.2M in 2023 to 10.5M in 2035, with 28% having uncontrolled gout. Annual costs of gout in CKD patients were projected to rise from $39.1B in 2023 to $50.4B in 2035. Pegloticase use in all CKD patients with uncontrolled gout resulted in 301,000 fewer uncontrolled gout cases, 208,000 quality-adjusted life years gained, and 53,000 complications avoided by 2035 (Figure). Compared to the baseline (non-treatment) scenario, intervention scenario costs were $23.4B lower in 2035. Conclusions: Gout prevalence in CKD patients is projected to markedly increase over the next 12 years. This microsimulation suggests that intervention could result in health and quality of life improvements in CKD patients with uncontrolled gout, with associated cost reductions. Funding: Commercial Support - Horizon Therapeutics plcFigure.: Difference in incident complications in CKD pts between treated (intervention) and untreated (baseline) uncontrolled gout scenarios.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NexusExplorer的应助被Alice3088采纳,获得10
1秒前
脑洞疼的应助被此时此刻采纳,获得10
1秒前
方囧完成签到,获得积分10
1秒前
福多多完成签到,获得积分10
2秒前
香蕉觅云的应助被Jack采纳,获得10
2秒前
巷陌发布了新的文献求助10
3秒前
wangjie完成签到,获得积分10
3秒前
科研通AI6.4的应助被温暖发箍采纳,获得10
4秒前
114514发布了新的文献求助10
4秒前
bkagyin的应助被1111A采纳,获得10
4秒前
cc发布了新的文献求助10
4秒前
kkkz发布了新的文献求助10
4秒前
彭于晏的应助被眼睛大羽毛采纳,获得10
5秒前
6秒前
133发布了新的文献求助10
6秒前
闪闪沧海完成签到 ,获得积分10
8秒前
Yu完成签到,获得积分10
8秒前
9秒前
9秒前
9秒前
10秒前
dfhh完成签到,获得积分20
10秒前
yuyan发布了新的文献求助10
10秒前
Auster发布了新的文献求助10
10秒前
在水一方的应助被Coral369采纳,获得10
11秒前
嘻嘻哈哈的应助被dzjin采纳,获得10
11秒前
初初初啊发布了新的文献求助10
12秒前
12秒前
拼搏飞柏发布了新的文献求助10
13秒前
14秒前
14秒前
WangChangman发布了新的文献求助10
14秒前
15秒前
JJ发布了新的文献求助10
15秒前
Jack发布了新的文献求助10
15秒前
汉堡包的应助被哦哦采纳,获得10
17秒前
inn关注了科研通微信公众号
18秒前
wangjkone完成签到,获得积分10
18秒前
loquatautumn完成签到 ,获得积分10
18秒前
CT完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165074
求助须知:如何正确求助?哪些是违规求助? 9558738
关于积分的说明 21747291
捐赠科研通 7755624
什么是DOI,文献DOI怎么找? 3428780
关于科研通互助平台的介绍 2553162
邀请新用户注册赠送积分活动 2473361